NO20005625L - Anvendelse av toremifen og dens metabolske analoger, og deres farmasoytisk akseptable salter, estere, N-oksider og blanding av disse, i fremstilling av et farmasoytisk preparat for behandling av prostataintraepitelisk neoplasi (PIN) - Google Patents

Anvendelse av toremifen og dens metabolske analoger, og deres farmasoytisk akseptable salter, estere, N-oksider og blanding av disse, i fremstilling av et farmasoytisk preparat for behandling av prostataintraepitelisk neoplasi (PIN)

Info

Publication number
NO20005625L
NO20005625L NO20005625A NO20005625A NO20005625L NO 20005625 L NO20005625 L NO 20005625L NO 20005625 A NO20005625 A NO 20005625A NO 20005625 A NO20005625 A NO 20005625A NO 20005625 L NO20005625 L NO 20005625L
Authority
NO
Norway
Prior art keywords
pin
intraepithelial neoplasia
toremifene
oxides
esters
Prior art date
Application number
NO20005625A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005625D0 (no
Inventor
Michell S Steiner
Sharon Raghow
Original Assignee
Univ Tennessee Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Corp filed Critical Univ Tennessee Res Corp
Publication of NO20005625D0 publication Critical patent/NO20005625D0/no
Publication of NO20005625L publication Critical patent/NO20005625L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20005625A 1998-05-07 2000-11-07 Anvendelse av toremifen og dens metabolske analoger, og deres farmasoytisk akseptable salter, estere, N-oksider og blanding av disse, i fremstilling av et farmasoytisk preparat for behandling av prostataintraepitelisk neoplasi (PIN) NO20005625L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8460298P 1998-05-07 1998-05-07
PCT/US1999/010146 WO1999056739A1 (en) 1998-05-07 1999-05-07 A method for chemoprevention of prostate cancer

Publications (2)

Publication Number Publication Date
NO20005625D0 NO20005625D0 (no) 2000-11-07
NO20005625L true NO20005625L (no) 2001-01-05

Family

ID=22186034

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005625A NO20005625L (no) 1998-05-07 2000-11-07 Anvendelse av toremifen og dens metabolske analoger, og deres farmasoytisk akseptable salter, estere, N-oksider og blanding av disse, i fremstilling av et farmasoytisk preparat for behandling av prostataintraepitelisk neoplasi (PIN)

Country Status (26)

Country Link
US (1) US6265448B1 (ja)
EP (3) EP1003496B1 (ja)
JP (2) JP4482229B2 (ja)
AT (1) ATE283043T1 (ja)
AU (1) AU761435B2 (ja)
BG (1) BG65597B1 (ja)
CA (1) CA2323809C (ja)
CZ (1) CZ300960B6 (ja)
DE (2) DE1003496T1 (ja)
DK (1) DK1003496T3 (ja)
EA (1) EA003466B1 (ja)
ES (1) ES2145730T3 (ja)
HR (1) HRP20000729A2 (ja)
HU (1) HUP0102068A3 (ja)
IL (3) IL138437A0 (ja)
IS (2) IS2213B (ja)
NO (1) NO20005625L (ja)
NZ (1) NZ527522A (ja)
PL (1) PL207462B1 (ja)
PT (1) PT1003496E (ja)
SI (1) SI1003496T1 (ja)
SK (1) SK16642000A3 (ja)
TR (1) TR200003269T2 (ja)
UA (1) UA74532C2 (ja)
WO (1) WO1999056739A1 (ja)
YU (1) YU68600A (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
JP4482229B2 (ja) * 1998-05-07 2010-06-16 ユニバーシティ オブ テネシー リサーチ ファウンデーション 前立腺癌の化学防御方法
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6413534B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6642274B1 (en) 1999-09-09 2003-11-04 Gary W. Neal Methods and compositions for preventing and treating prostate disorders
EP1214038A2 (en) * 1999-09-09 2002-06-19 Androsolutions, Inc. Methods and compositions for preventing and treating prostate disorders
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040096510A1 (en) * 2001-11-29 2004-05-20 Steiner Mitchell S. Prevention and treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
BR0214801A (pt) 2001-11-29 2005-01-11 Gtx Inc Prevenção e tratamento de osteoporose induzida pela privação de andrógeno
US20040213841A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S Methods for treating hot flashes and gynecomastia
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US7070816B2 (en) * 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
US20050208159A1 (en) * 2004-03-16 2005-09-22 Kang Kyung S Phytoestrogenic composition comprising an extract of chinese licorice root, liquiritin or isoliquiritin
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
USD969722S1 (en) 2021-09-28 2022-11-15 Wagner Delima Stabilizing wedge pad

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329364A (en) 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4474813A (en) 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
FI77839C (fi) * 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US4990538A (en) 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
GB9126209D0 (en) * 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US5847007A (en) 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
DE69329802T2 (de) * 1992-12-01 2001-07-19 Biotie Therapies Corp Syndecan-stimulierung der zellulären differenzierung
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
RU2153332C2 (ru) 1993-08-09 2000-07-27 Орион Корпорейшн Способ сенсибилизации раковых клеток к лизису, опосредованному клетками-киллерами
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5635197A (en) 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
US5629007A (en) 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
ZA984650B (en) 1997-06-19 1998-12-08 Orion Corp Intratumoral administration of triphenylethylenes for the treatment of cancer
JP4482229B2 (ja) * 1998-05-07 2010-06-16 ユニバーシティ オブ テネシー リサーチ ファウンデーション 前立腺癌の化学防御方法

Also Published As

Publication number Publication date
IL193231A0 (en) 2009-02-11
IL138437A (en) 2008-12-29
JP4482229B2 (ja) 2010-06-16
EA003466B1 (ru) 2003-06-26
TR200003269T2 (tr) 2001-02-21
ES2145730T3 (es) 2005-06-16
CZ300960B6 (cs) 2009-09-23
HUP0102068A3 (en) 2002-11-28
HRP20000729A2 (en) 2001-06-30
YU68600A (sh) 2003-12-31
WO1999056739A1 (en) 1999-11-11
CZ20004118A3 (cs) 2002-07-17
DE69922131T2 (de) 2005-11-24
CA2323809C (en) 2007-09-18
DE1003496T1 (de) 2000-11-02
IL138437A0 (en) 2001-10-31
AU761435B2 (en) 2003-06-05
IS2213B (is) 2007-03-15
NZ527522A (en) 2005-04-29
AU4072699A (en) 1999-11-23
EP1475087A2 (en) 2004-11-10
SI1003496T1 (en) 2005-10-31
ES2145730T1 (es) 2000-07-16
EP1475087A3 (en) 2007-07-11
ATE283043T1 (de) 2004-12-15
DK1003496T3 (da) 2005-04-04
SK16642000A3 (sk) 2002-08-06
EA200000100A1 (ru) 2000-08-28
US6265448B1 (en) 2001-07-24
HUP0102068A2 (hu) 2002-05-29
PL207462B1 (pl) 2010-12-31
PL344000A1 (en) 2001-09-10
BG65597B1 (bg) 2009-02-27
UA74532C2 (en) 2006-01-16
IS8354A (is) 2006-03-15
PT1003496E (pt) 2005-04-29
BG105022A (bg) 2001-07-31
DE69922131D1 (de) 2004-12-30
CA2323809A1 (en) 1999-11-11
EP2277514A1 (en) 2011-01-26
JP2008163048A (ja) 2008-07-17
NO20005625D0 (no) 2000-11-07
JP2002513755A (ja) 2002-05-14
EP1003496A1 (en) 2000-05-31
EP1003496B1 (en) 2004-11-24
IS5700A (is) 2000-11-01

Similar Documents

Publication Publication Date Title
NO20005625L (no) Anvendelse av toremifen og dens metabolske analoger, og deres farmasoytisk akseptable salter, estere, N-oksider og blanding av disse, i fremstilling av et farmasoytisk preparat for behandling av prostataintraepitelisk neoplasi (PIN)
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
WO2003030829A3 (en) Liposome-encapsulated insulin formulations
AU7888398A (en) Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
BR9503386A (pt) Formulaçao farmacêutica comprimido dispersivel e processo para a fabricaçao de comprimidos dispersíveis contendo cloridrato de fluoxetina
ATE544447T1 (de) Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
WO2002022598A8 (en) Quinolinone derivatives as tyrosine kinase inhibitors
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
EP0943331A3 (en) Formulations containing oxaliplatin
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
AU2624400A (en) Monodisperse hexameric acylated insulin analog formulations
BR0210489A (pt) Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente
CA2336945A1 (en) Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
ATE372774T1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
WO2002092565A3 (en) 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
MXPA04001805A (es) Nueva forma de dosificacion oral de liberacion prolongada.
YU19302A (sh) 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
MXPA02012957A (es) Formulacion nueva.
WO2003024394A3 (en) Method of treating benign prostatic hyperplasia and other beingn porstate conditions
EP1297838A4 (en) PRALMORELIN-CONTAINED NOSE DROP PREPARATIONS
AP1820A (en) Use of specific dose of fondaparinux sodium for the treatment of ACS.
WO2002094183A3 (en) A method for tumor treatment with fumagillol derivatives
WO2001030324A3 (de) Verwendung von acetylsalicylsäure sowie zubereitung zur behandlung von prostatahyperplasie

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application